Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Absence of fibroblast growth factor 2 does not prevent tumor formation originating from the RPE

Oncogene volume 21, pages 1841–1847 (2002)Cite this article

Abstract

We have analysed the importance of fibroblast growth factor 2 (FGF2) in tumor development. In a transgenic mouse model (Tyrp1-Tag) tumors form in the retinal pigment epithelium (RPE), invade surrounding tissues, and metastasize to lymph node and spleen. To address whether RPE tumor formation is dependent on FGF2, we generated FGF2-deficient mice. Such mice appeared healthy and exhibited no impairment of growth or development. Tyrp1-Tag transgenic mice, which are lacking FGF2 (FGF2−/−) developed RPE tumors that metastasize to spleen and lymph nodes. Tumor growth and survival rate are identical to Tyrp1-Tag transgenic littermates expressing FGF2. Cell lines were isolated from RPE tumors of wild-type and FGF2-deficient mice. They grow in culture, are pigmented and form vascularized tumors, when injected subcutaneously into nude mice of either FGF2−/− or FGF2+/+ genetic background. Kinetics of tumor growth was identical and independent of presence of FGF2. Together, these results demonstrate that FGF2 is not essential for tumor formation of the RPE thus suggesting that tumor growth in general may not be dependent on FGF2.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Anand R, Ma D, Alizadeh H, Comerford S, Sambrook J, Gething M, McLean I, Niederkorn J . 1994 Invest. Ophthalmol. Vis. Sci. 35: 3533–3539

  • Becker D, Meier CB, Herlyn M . 1989 EMBO J. 8: 3685–3691

  • Beermann F, Hunziker A, Foletti A . 1999 Pigment Cell Res. 12: 71–80

  • Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M . 2001 Am. J. Pathol. 158: 943–953

  • Bikfalvi A, Klein S, Pintucci G, Rifkin D . 1997 Endocrine Rev. 18: 26–45

  • Bradl M, Klein-Szanto A, Porter S, Mintz B . 1991 Proc. Natl. Acad. Sci. USA 88: 164–168

  • Bryckaert M, Guillonneau X, Hecquet C, Courtois Y, Mascarelli F . 1999 Oncogene 18: 7584–7593

  • Crickard K, Gross JL, Crickard U, Yoonessi M, Lele S, Herblin WF, Eidsvoog K . 1994 Gyn. Oncol. 55: 277–284

  • del Marmol V, Beermann F . 1996 FEBS Lett. 381: 165–168

  • Dono R, Texido G, Dussel R, Ehmke H, Zeller R . 1998 EMBO J. 17: 4213–4225

  • Dotto GP, Moellmann G, Ghosh S, Edwards M, Halaban R . 1989 J. Cell Biol. 109: 3115–3128

  • el Yazidi I, Boilly MY . 1995 Anticancer Res. 15: 783–790

  • Feldman B, Poueymirou W, Papaioannou V, DeChiara T, Goldfarb M . 1995 Science 267: 246–249

  • Fiore F, Planche J, Gibier P, Sebille A, deLapeyriere O, Birnbaum D . 1997 Int. J. Dev. Biol. 41: 639–642

  • Frank R, Amin R, Eliott D, Puklin J, Abrams G . 1996 Am. J. Ophthalmol. 122: 393–403

  • Guo L, Degenstein L, Fuchs E . 1996 Genes Dev. 10: 165–175

  • Hackett S, Schoenfeld C, Freund J, Gottsch J, Bhargave S, Campochiaro P . 1997 Exp. Eye Res. 64: 865–873

  • Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A . 1988 Oncogene Res. 3: 177–186

  • Hanahan D, Folkman J . 1995 Cell 86: 353–364

  • Hébert JM, Rosenquist T, Götz J, Martin GR . 1994 Cell 78: 1017–1025

  • Hummler E, Barker P, Gatzy J, Beermann F, Verdumo C, Schmidt A, Boucher R, Rossier B . 1996 Nature Genet. 12: 325–328

  • Jordan S, Beermann F . 2000 Pigment Cell Res. 13: 70–71

  • Kaestner KH, Montoliu L, Kern H, Thulke M, Schütz G . 1994 Gene 148: 67–70

  • Loeffler KU, Kivela T, Borgmann H, Witschel H . 1996 Graefes Arch. Clin. Exp. Ophthalm. 234: 70–75

  • MacArthur H, Walter G . 1984 J. Virol. 52: 483–491

  • Magin T, McWhir J, Melton D . 1992 Nucl. Acids Res. 20: 3795–3796

  • Mansour SL, Goddard JM, Capecchi MR . 1993 Development 117: 13–28

  • Maret A, Galy B, Arnaud E, Bayard F, Prats H . 1995 Cancer Res. 55: 5075–5079

  • Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J . 1996 Blood 87: 1056–1063

  • Miller D, Ortega S, Bashayan O, Basch R, Basilico C . 2000 Mol. Cell. Biol. 20: 2260–2268

  • Mintz B, Klein-Szanto AJP . 1992 Proc. Natl. Acad. Sci. USA 89: 11421–11425

  • Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin J, Hurley M . 2000 J. Clin. Invest. 105: 1085–1093

  • Mousa S, Lorelli W, Campochiaro P . 1999 J. Cell. Biochem. 74: 135–143

  • Nguyen M, Arnheiter H . 2000 Development 127: 3581–3591

  • Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J . 1994 J. Natl. Canc. Inst. 86: 356–361

  • O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL . 1997 Cancer Res. 57: 136–140

  • Ogata N, Matsushima M, Takada Y, Tobe T, Takahashi K, Ye X, Yamamoto C, Yamada H, Uyama M . 1995 Curr. Eye Res. 15: 1008–1018

  • Opas M, Dziak E . 1994 Dev. Biol. 161: 440–454

  • Ortega S, Ittmann M, Tsang S, Ehrlich M, Basilico C . 1998 Proc. Natl. Acad. Sci. USA 95: 5672–5677

  • Ozaki H, Okamoto N, Ortega S, Chang M, Ozaki K, Sadda S, Vinores M, Derevjanik N, Zack D, Basilico C, Campochiaro P . 1998 Am. J. Pathol. 153: 757–765

  • Pellieux C, Foletti A, Peduto G, Aubert JF, Nussberger J, Beermann F, Brunner HR, Pedrazzini T . 2001 J. Clin. Invest. in press

  • Penna D, Schmidt A, Beermann F . 1998 Oncogene 17: 2601–2607

  • Rakoczy P, Humphrey M, Cavaney D, Chu Y, Constable I . 1993 Invest. Ophthalmol. Vis. Sci. 34: 1845–1852

  • Reed JA, McNutt NS, Albino AP . 1994 Am. J. Pathol. 144: 329–335

  • Sakaguchi D, Janick L, Reh T . 1997 Dev. Dyn. 209: 387–398

  • Schmidt A, Tief K, Foletti A, Hunziker A, Penna D, Hummler E, Beermann F . 1998 Brain Res. Prot. 3: 54–60

  • Schultz J, Witt S, Nieman M, Reiser P, Engle S, Zhou M, Pawloswski S, Lorenz J, Kimball T, Doetschman T . 1999 J. Clin. Invest. 104: 709–719

  • Scott G, Stoler M, Sarkar S, Halaban R . 1991 J. Invest. Dermatol. 96: 318–322

  • Sekine K, Ohuchi H, Fujiwara M, Yamasaki M, Yoshizawa T, Sato T, Yashigata N, Matsui D, Koga Y, Itoh N, Kato S . 1999 Nature Genet. 21: 138–141

  • Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C . 1995 Anticancer Res. 15: 2675–2677

  • Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M . 1992 J. Neurosurg. 76: 792–798

  • Tobe T, Ortega S, Luna J, Ozaki H, Okamoto N, Derevjanik N, Vinores S, Basilico C, Campochiaro P . 1998 Am. J. Pathol. 153: 1641–1646

  • Vaccarino F, Schwartz M, Raballo R, Nilsen J, Rhee J, Zhou M, Doetschman T, Coffin J, Wyland J, Hung Y . 1999 Nature Neurosci. 2: 246–253

  • Vagner S, Touriol C, Galy B, Audigier S, Gensac M, Amalric F, Bayard F, Prats H, Prats A . 1996 J. Cell. Biol. 135: 1391–1402

  • Wang Y, Becker D . 1997 Nature Med. 3: 887–893

  • Zhou M, Sutliff R, Paul R, Lorenz J, Hoying J, Haudenschild C, Yin M, Coffin J, Kong L, Kranias E, Luo W, Boivin G, Duffy J, Pawlowski S, Doetschman T . 1998 Nature Med. 4: 201–207

  • Zuniga Mejia Borja A, Murphy C, Zeller R . 1996 Dev. Biol. 180: 680–692

Download references

Acknowledgements

Thanks are due to Curzio Ruegg and David Hicks for helpful comments, to Estelle Säuberli and Giovanna Badic-Benedotto for help with histology, and to Sophie Javerzat for FGF2 antibody. Work was supported by grants from the Krebsforschung Schweiz (KFS – 00602-11998), the Krebsliga des Kantons Schaffhausen and the Swiss National Science Foundation.

Author information

Authors and Affiliations

  1. ISREC (Swiss Institute for Experimental Cancer Research), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland

    Alessandro Foletti, Julien Ackermann, Andrea Schmidt & Friedrich Beermann

  2. Institute of Pharmacology and Toxicology, University of Lausanne, Bugnon 27, CH-1005 Lausanne, Switzerland

    Edith Hummler

Authors
  1. Alessandro Foletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julien Ackermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edith Hummler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Friedrich Beermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Friedrich Beermann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Foletti, A., Ackermann, J., Schmidt, A. et al. Absence of fibroblast growth factor 2 does not prevent tumor formation originating from the RPE. Oncogene 21, 1841–1847 (2002). https://doi.org/10.1038/sj.onc.1205030

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205030

Keywords

Search

Advanced search

Quick links